Company: RPID
Filing Date: 2025-04-08
Form Type: DEF 14A
Source: 0001380106-25-000089
Chunk: 17

Company: RAPID MICRO BIOSYSTEMS, INC.
Filing Date: 2025-04-08
Form: DEF 14A
Chunk 17
---
 Senior Vice President and Global Head of Pharmaceutical Technology and Development at AstraZeneca plc (Nasdaq: AZN) (“AstraZeneca”) since April 2016, where she leads a global team of scientists and engineers to drive the transformation of synthetic molecules into approved medicines. Prior to joining AstraZeneca, Dr. Bika held roles of increasing responsibility at Bristol-Myers Squibb Company (NYSE: BMY), serving as Executive Director of Manufacturing Technology, Packaging Technology and Device Operations from September 2009 to July 2012, and as Vice President of Global Drug Product Manufacturing Science and Technology from July 2012 to April 2016. Previously, from April 1999 to August 2009, Dr. Bika served as the Director of Global Pharmaceutical Commercialization at Merck &Co., Inc. (NYSE: MRK). Dr. Bika holds a Ph.D. in Materials Science and Engineering from the University of Pennsylvania, a Master of Science in Materials Science and Engineering from the University of Rochester, NY, and a Diploma in Chemical Engineering from the National Technical University of Athens. We believe that Dr. Bika’s extensive experience in pharmaceutical development and technology at large biopharmaceutical companies qualify her to serve on our Board. VOTE REQUIRED The proposal regarding the election of directors requires the approval of a plurality of the votes cast to elect a director. This means that the nominees receiving the highest number of affirmative “FOR” votes will be elected as Class I Directors. Votes withheld and broker non-votes will have no effect on the outcome of the election of directors. RECOMMENDATION OF THE BOARD OF DIRECTORS

| Ü |     | Our Board unanimously recommends a vote FOR the elections of Inese Lowenstein and Dafni Bika as Class I Directors to serve until the 2028 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified, or until their earlier death, resignation or removal. |

10

TABLE OF CONTENTS PROPOSAL 2: Ratification of Appointment of Independent Registered Public Accounting Firm Our Audit Committee has appointed PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025. Our Board has directed that this appointment be submitted to our stockholders for ratification. Although ratification of our appointment of PricewaterhouseCoopers LLP is not required by law or Nasdaq rules, we value the opinions of our stockholders and our Audit Committee believes that stock